Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)

Market Cap	40.03B +48.5%
Revenue (ttm)	6.88B +12.8%
Net Income	1.14B +35.1%
EPS	3.13 +32.4%
Shares Out	n/a
PE Ratio	35.26
Forward PE	25.97
Dividend	1.20 (1.36%)
Ex-Dividend Date	Jun 25, 2025

Volume	125,860
Average Volume	226,995
Open	82.10
Previous Close	83.05
Day's Range	80.80 - 82.95
52-Week Range	39.95 - 116.60
Beta	0.23
RSI	46.52
Earnings Date	Mar 31, 2026

About HKG:6821

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers API solutions, such as small molecules, highly potent, carbapenems, glycans, peptides, oligonucleotides, and therapeutic enzymes; GMP, non-GMP, asymchem lab facilities and capabilities, commercial manufacturing, clinical manufacturing, separations, crystallization, fermentation, continuous FlowGMP, non-GMP, Asymchem lab facilities and capabilities, commercial manufacturing...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 9,595
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2024, HKG:6821's revenue was 5.80 billion, a decrease of -25.82% compared to the previous year's 7.83 billion. Earnings were 948.95 million, a decrease of -58.17%.

Financial numbers in CNY